Tagged with Global

Global Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park highlights key takeaways from the BIOJapan 2020 conference on why San Diego offers a good example of what it takes to be a leader in the innovative life science sector.   Over the past two decades, drug discovery has undergone…

Global COVID-19 has drawn global attention to the sorry state of funding and R&D investment in vaccine development and pandemic prevention, but other previously neglected areas of health research are also now entering the spotlight. One of these underfunded areas is mental health and neurological disorders, leading a global group of…

Global Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight, and makes three bold predictions for the future of the field, especially in emerging countries.   As a true believer in the power of technology to transform health,…

Global Merck Healthcare’s newly appointed Global Head of Business innovation, Renée C. Amundsen, highlights the numerous opportunities for change management that the COVID-19 pandemic has thrown up, why company-HCP interaction might never be the same again, and shares some pearls of wisdom for other women in pharma.   I see Merck’s…

Opinion Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the myriad benefits of collaborative, as opposed to command, leadership, the impact of company and team culture on the innovation journey, and why we must not confuse collaboration with…

Talent COVID-19 has necessitated enormous shifts in the way we live, work, and communicate with each other. Nowhere is this more apparent professionally than for those starting a new job. Here, we highlight four recent appointees to new roles in pharma companies across Europe and the USA and how they have…

Global UNICEF’s Eva Kadilli outlines the work that the organisation’s supply division is undertaking in the global push for a COVID-19 vaccine, the impact of the pandemic on immunisation programs for other diseases globally, and makes a call for further solidarity between stakeholders across the public sector, private industry, and civil…

Global Dr Muhammad Ali Pate, Global Director for Health, Nutrition and Population at the World Bank as well as Director of the Global Financing Facility for Women, Children and Adolescents, reflects on the impact of the current COVID-19 pandemic on the work that the global institution has been doing to promote…

M&A In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition of Momenta Pharmaceuticals for USD 6.5 billion, a further signal of Big Pharma’s prioritisation of rare disease treatments.   The all-cash deal sees J&J’s pharmaceutical division…

Merck PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to rise to the supply chain challenges posed by the COVID-19 crisis.   Although many companies now claim to have this…

Opinion In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order to secure investments into the right kinds of R&D and to help build a more open and collaborative innovation ecosystem.…

Opinion Jessica Scott, Takeda’s head of R&D patient engagement, highlights how a better understanding of the value of patient engagement across the healthcare stakeholder spectrum will drive better health outcomes and why keeping an open and curious mindset is crucial in this endeavour.   By incorporating Patient Engagement (PE) into the…